Nyxoah SA announced on September 23, 2025, the continued expansion of its commercial footprint in the Middle East. This expansion follows the first successful Genio® implant in Abu Dhabi in September 2025, building on the initial launch in the region earlier in the year.
The company is partnering with leading healthcare institutions in Dubai, Kuwait, and Abu Dhabi to broaden access to its Genio system. This strategic expansion aims to improve outcomes for patients suffering from Obstructive Sleep Apnea (OSA) who are unable to tolerate CPAP.
Olivier Taelman, Chief Executive Officer of Nyxoah, highlighted the Middle East as an important and growing market for the company. This move reinforces Nyxoah's commitment to delivering its leadless, externally powered bilateral hypoglossal nerve stimulation system to a wider patient population globally.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.